报告题目🍾：Identify therapeutic targets in lung cancer by CRISPR screen

报告人：彭仁旺 瑞士伯尔尼大学医天美PI，教授

主持人🙋🏻：叶海峰 教授

报告时间：12月7日下午13:30（周四下午）

报告地点： 天美娱乐534小会议室

主办单位：天美娱乐，科技处

 

报告人简介： 彭仁旺，中国科天美微生物研究所博士，德国马普生物物理化学研究所博士后🧏🏿‍♂️，美国达特茅斯医天美访问学者。2006-2011年苏黎世联邦理工大学PI🍵。现为瑞士伯尔尼大学医天美PI，教授，博士生导师。主持由瑞士国家癌症基金会资助的课题多项🫅。以第一作者和通讯作者在Science, PNAS, J. Cell Biol., EMBO J. 等发表论文多篇➙。

 

研究领域: 细胞生物学，干细胞生物学，肿瘤分子生物学。

 

报告内容简介：Lung cancer is the leading cause of cancer death worldwide, making the development of new and effective therapeutic interventions to improve clinical outcome of lung cancer patients a desperate demand, which, however, remains an unmet endeavor. Our lab is interested in lung cancer therapeutic resistance, a notoriously known clinic challenge in cancer treatment. We have applied CRISPR/Cas9 genome-editing tools to identity cancer genes and pathways that render lung cancer resistant to current therapies. This approach enables rapid identification and validation of new drug targets and modelling of lung cancer therapeutic resistance in vitro and in vivo, bringing about unprecedented possibilities to understand the biology of lung cancer and to attack the most common and deadliest human cancer.